Tectonic Therapeutic, Inc. (TECX)
NASDAQ: TECX · Real-Time Price · USD
23.45
-0.48 (-2.01%)
Feb 27, 2026, 4:00 PM EST - Market closed
Tectonic Therapeutic Employees
Tectonic Therapeutic had 51 employees as of December 31, 2024. The number of employees increased by 7 or 15.91% compared to the previous year.
Employees
51
Change
7
Growth
15.91%
Revenue / Employee
n/a
Profits / Employee
-$1,453,941
Market Cap
438.90M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 51 | 7 | 15.91% |
| Mar 31, 2024 | 45 | - | - |
| Dec 31, 2023 | 44 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 353 |
| Entrada Therapeutics | 183 |
| Prothena Corporation | 163 |
| Kyverna Therapeutics | 129 |
| Keros Therapeutics | 82 |
| Verastem | 78 |
| Assembly Biosciences | 73 |
| PepGen | 57 |
TECX News
- 1 day ago - Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 4 days ago - Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board - GlobeNewsWire
- 16 days ago - Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026 - GlobeNewsWire
- 3 months ago - Tectonic: Strong Buy On Positive Phase 1b TX45 Data And 2026 Inflection Point - Seeking Alpha
- 4 months ago - Tectonic Therapeutic, Inc. (TECX) Discusses Positive Topline Results From Phase Ib Part B Trial of TX45 in PH-HFrEF Patients Transcript - Seeking Alpha
- 4 months ago - Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF - GlobeNewsWire
- 6 months ago - Tectonic Therapeutic to Participate in September Investor Conferences - GlobeNewsWire
- 8 months ago - Tectonic Therapeutic Joins Russell 3000® Index - GlobeNewsWire